Search Results for keywords:"DEA"

The Drug Enforcement Administration (DEA) temporarily placed a substance called brorphine in Schedule I of the Controlled Substances Act due to its high potential for abuse, lack of accepted medical use, and potential danger to public safety. This action means strict regulatory controls are now in place regarding the manufacturing, distribution, and possession of brorphine. The DEA found brorphine on the illicit market in several countries and associated it with several fatalities in the U.S. Brorphine is a synthetic opioid with effects similar to fentanyl, which poses significant health risks and has been linked to the ongoing opioid epidemic. This temporary scheduling will last for two years and can be extended for an additional year.

The Drug Enforcement Administration (DEA) has proposed a new rule to allow healthcare practitioners to prescribe controlled substances via telemedicine, without needing an in-person exam, through a Special Registration framework. This framework permits three types of special registrations: Telemedicine Prescribing Registration for Schedule III-V drugs, Advanced Telemedicine Prescribing Registration for Schedule II-V drugs for certain specialists, and Telemedicine Platform Registration for online platforms to dispense these drugs. These changes, which aim to expand patient access while safeguarding against drug abuse, also require practitioners to perform additional prescription checks and comply with detailed reporting and recordkeeping. Public comments on this proposal are welcome before final implementation.

The Department of Justice, specifically the Drug Enforcement Administration (DEA), is requesting public feedback on a proposed information collection related to emergency medical services and controlled substances. This proposal aims to ensure compliance with the Controlled Substances Act by setting new recordkeeping standards for emergency medical services agencies. These standards involve maintaining records of controlled substances used by these agencies, which include details about administration, disposal, and delivery. The DEA encourages comments on the necessity, burden, and clarity of this information collection until January 13, 2025, as part of their efforts to secure approval for a three-year authorization under the Paperwork Reduction Act.

The Drug Enforcement Administration (DEA) is proposing to place the substance 4-chloromethcathinone (4-CMC) in schedule I of the Controlled Substances Act. This move aims to impose strict regulations similar to other highly controlled drugs, as 4-CMC is known to have a high potential for abuse and no accepted medical use in the U.S. The decision also helps the United States comply with international agreements on psychotropic substances. Public comments on this proposal are accepted until January 29, 2025.